Get the latest news on immunotherapy

November 13, 2020

Pembrolizumab approved in triple-negative breast cancer (TNBC)

November 8, 2020

Phase 2 Study Finds Nivolumab-Ipilimumab Combo Shows Activity in Metastatic Uveal Melanoma

November 7, 2020

TMB Use as Immunotherapy Biomarker Fraught by Challenges, But Still Shows Potential

November 6, 2020

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer

November 6, 2020

NICE rules nivolumab is not cost effective for use on NHS

November 3, 2020

Studies Find Connection Between Age and Melanoma Treatment Resistance

November 2, 2020

Libtayo Given FDA Priority Review for Advanced NSCLC With High PD-L1 Levels

November 2, 2020

Castle Biosciences Announces Commercial Launch of DecisionDx DiffDx-Melanoma

October 31, 2020

Cabozantinib Plus Nivolumab Improves Efficacy Over Sunitinib in mRCC

October 19, 2020

How Do Melanoma Comorbidities Affect Patient Treatment Preferences?

September 21, 2020

ESMO 2020 Virtual Conference: Immunomedics wows ESMO with breast cancer data reveal

September 21, 2020

ESMO 2020 Virtual Conference: Late-breaking ESMO Presentation Shows Libtayo® (cemiplimab) Monotherapy Increases Overall Survival in First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%

September 21, 2020

ESMO 2020 Virtual Conference: QUANTITATIVE SUMMARY OF QOL DATA CONFIRMS IMMUNE CHECKPOINT INHIBITOR THERAPY IS GENERALLY WELL-TOLERATED

September 21, 2020

ESMO Virtual Conference 2020: IMMUNOTHERAPY IS BENEFICIAL IN GASTRIC AND ESOPHAGEAL CANCERS, STUDIES SHOW

September 20, 2020

ESMO 2020 Virtual Conference: PEMBROLIZUMAB DELIVERS CLINICAL BENEFIT IN SELECTED HISTOTYPES OF RARE SARCOMA

September 19, 2020

ESMO 2020 Virtual Conference: Results for Sacituzumab govitecan-hziy in breast and bladder support this antibody-drug conjugate

September 19, 2020

ESMO Virtual Conference 2020: Results from IO Therapy for Triple Negative Breast Cancer

September 19, 2020

ESMO Virtual Conference 2020: Nivolumab and cabozantinib effective in first-line treatment for metastatic kidney cancer

September 18, 2020

Durvalumab demonstrated unprecedented survival in unresectable, Stage III non-small cell lung cancer with an estimated 50% of patients surviving four years

September 18, 2020

2020 ESMO Virtual Congress 2020: Positive pivotal data for Libtayo® (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at ESMO

September 17, 2020

ESMO Virtual Congress 2020: Nivolumab + Ipilimumab vs. Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma in CheckMate 214: 4-Year Follow-up and Subgroup Analysis of Patients without Nephrectomy

September 14, 2020

Adjuvant Opdivo shows promise in Esophageal-GEJ Cancer Patients

September 12, 2020

Higher Microbial Diversity May Be Associated with Better Outcomes in Patients with RCC

September 10, 2020

Validation of AI tools for cancer immunotherapy may be a step closer

September 10, 2020

Nivolumab/ipilimumab dual immune-checkpoint blockade active in mCRPC

September 8, 2020

Nivolumab/Ipilimumab Established as New Standard in Frontline sRCC

August 20, 2020

Merck’s oral cancer drug targeting STING boosts PD-1 immune blockade in mice

August 20, 2020

Immunotherapy Combo Shows Positive Results for Mesothelioma

August 19, 2020

Young Female Patients Have Low Response Rates to Immunotherapy

August 19, 2020

Pembrolizumab regimen extends survival in advanced esophageal cancer

August 19, 2020

Greater Diversity in Gut Microbiome Associated with Better Cancer Immunotherapy Outcomes

August 18, 2020

New App Helps Clinicians Manage Checkpoint Inhibitor AEs

August 15, 2020

CAR-NK Cell Immunotherapy Shows Promise

July 30, 2020

FDA Approves Atezolizumab Targeted Therapy Triple Combo for BRAF V600 Unresectable or Metastatic Melanoma

June 29, 2020

Cancer Vaccine Combo to be Tested in Triple Negative Breast Cancer

June 29, 2020

FDA Approves First-Line Immunotherapy for Patients with MSI-H/dMMR Metastatic Colorectal Cancer

June 27, 2020

Fecal Microbiota Transplant May Emerge as a Treatment Strategy in Melanoma Following Immunotherapy Failure

June 25, 2020

Noadjuvant Melanoma Combo Improves RFS in Macroscopic Melanoma

June 24, 2020

FDA Approves Pembrolizumab for Cutaneous Squamous Cell Carcinoma

June 9, 2020

Dramatic Drop in Skin Cancer Referrals During COVID-19 Crisis

June 8, 2020

New findings with immunotherapy in the adjuvant setting for Merkel Cell Carcinoma

June 8, 2020

Microbiotica, Cancer Research UK and Cambridge University Hospitals Collaborate in Landmark Cancer Microbiome Study

June 8, 2020

Personalized treatment strategies in melanoma could reduce toxicity burden from immunotherapy without compromising benefits

June 3, 2020

Replimune Provides RP1 Data Update from its Phase 2 Cohorts in Melanoma and Non-Melanoma Skin Cancer that Strongly Support Replimune’s Ongoing Registration-Directed Clinical Trials with RP1

May 28, 2020

Immunotherapy Avelumab Shows Potential in Rare Gynecologic Cancer Resistant to Chemotherapy

May 28, 2020

Pembrolizumab Doubles Time to Disease Progression in Patients With Advanced Colorectal Cancer With Specific DNA Mutations

May 18, 2020

FDA Approves Atezolizumab as a First-Line Treatment for Metastatic NSCLC Subgroup

April 28, 2020

FDA Approves Every-6-Week Pembrolizumab Dosage

April 27, 2020

Data Demonstrate Efficacy and Safety of KEYTRUDA 400 mg Every Six Weeks (Q6W) Comparable to Approved 200 mg Every Three Weeks (Q3W) Regimen

April 27, 2020

Atezolizumab Plus Vemurafenib/Cobimetinib Impresses in BRAF V600+ Melanoma

April 10, 2020

Checkpoint Combo Runs the Table in Early CRC

March 31, 2020

Skin Cancer Education & Research Foundation Launches New Website – A New Resource for the Fight Against Skin Caner.

March 25, 2020

Seattle Cancer Care Alliance, at the epicenter of the US epidemic, provides insights for cancer care during the evolving the COVID-19 crisis.

February 12, 2020

Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (mTNBC)

February 12, 2020

Dealing with Coronavirus (COVID-19): Recommendations from the CDC

February 11, 2020

Seattle Genetics, Astellas, and Merck Hit a Bladder Cancer Bullseye

February 11, 2020

Jounce Using New Predictive Biomarker to Select Patients for Upcoming Phase II Immunotherapy Trial

February 10, 2020

Geneos to Test GNOS-PV02 Cancer Vaccine in Triple Combo Trial for Advanced Liver Cancer

February 3, 2020

First Patient Dosed in Proof-of-concept Study of CS1001 Plus Stivarga for Advanced Solid Tumors

January 26, 2020

Genentech Submits Supplemental Biologics License Application to the FDA for Tecentriq in Combination With Avastin for the Most Common Form of Liver Cancer

January 23, 2020

FDA to Review Tecentriq-Avastin Combo for Newly Diagnosed Advanced Liver Cancers

January 15, 2020

U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Non-Small Cell Lung Cancer

January 13, 2020

Influenza Vaccines Triggers Immune System Response in Tumors

January 12, 2020

Positive Final 2-Year Topline Data in Completed DC Vaccine Phase I/II trial in AML Patients

January 11, 2020

Early-Stage Leukemia Vaccine Study Reports 80% Survival Rate

January 8, 2020

FDA approves Keytruda for BCG-unresponsive, high-risk non-muscle invasive bladder cancer

January 8, 2020

U.S. cancer death rate sees largest yearly drop

January 3, 2020

Tislelizumab-Chemo Combo Induces Durable Responses in Patients with Stomach, Esophagus Cancers, Trial Data Show

December 13, 2019

Genentech Announces Phase III Study Results for Tecentriq Plus Cotellic and Zelboraf in People With Previously Untreated BRAF V600 Mutation-positive Advanced Melanoma

December 9, 2019

ASH 2019: Brentuximab Vedotin in Combination with Nivolumab in Frontline and R/R Hodgkin Lymphoma

December 9, 2019

Nivolumab shows promise in ‘wide variety’ of mismatch repair-deficient cancers

December 8, 2019

Experimental immunotherapy can put patients with relapsed or refractory lymphoma into remission

December 8, 2019

ALX Oncology Presents Initial Data from the ALX148 Clinical Trial Non-Hodgkin Lymphoma Combination Cohort at the 61st American Society of Hematology (ASH)

December 8, 2019

Hyperprogression Halts Study of Nivolumab in Peripheral T-Cell Lymphomas

December 8, 2019

Speeding Access To New And Innovative Cancer Treatments

November 20, 2019

Opdivo/Yervoy combo for melanoma fails in key patient population

November 1, 2019

5-year survival data positive for nivolumab-based regimens in advanced melanoma

November 1, 2019

STING pathway may be key to tumor cell recognition by immune cells

October 29, 2019

ASDS Steering committee develops evidence-based consensus on cSCC staging, workup, treatment

October 28, 2019

Managing Hematological Immune-Related Adverse Events With Immune Checkpoint Inhibitors

October 28, 2019

Nivolumab improves survival in non-small cell lung carcinoma, study results suggest

October 28, 2019

IMFINZI® (durvalumab) and IMFINZI Plus Tremelimumab Delayed Disease Progression in Phase III POSEIDON Trial for 1st-Line Treatment of Stage IV Non-Small Cell Lung Cancer

October 28, 2019

Keytruda Survival Benefits Similar to Chemo for Relapsed Mesothelioma, Phase 3 Trial Finds

September 27, 2019

Maeton’s OT101 Gets Rare Pediatric Disease Designation for Childhood Brain Tumor

September 27, 2019

Systemic immune response in squamous cell carcinoma of the head and neck: A comparative concordance index analysis

September 26, 2019

Tasmanian devil research could help tackle immunotherapy resistance

September 26, 2019

Cognitive Impairment Following Immunotherapy Treatment May Be Underestimated

September 26, 2019

IL-10-based therapy shows promise when used in combination with anti-PD1 agents in lung and RCC

September 26, 2019

Metabolic Imbalance Associated with Resistance to Checkpoint Inhibitor Nivolumab

September 26, 2019

Boost in Survival Rates for Younger Patients With Melanoma Attributed to Immunotherapy Agents

September 4, 2019

Nivolumab more effective versus investigator’s choice in younger vs older patients with recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141)

September 4, 2019

TGF-Beta may be a predictive biomarker for response to pembrolizumab in HCC

September 3, 2019

Pooled Analysis Shows Triple OS with Nivolumab in Advanced NSCLC

August 30, 2019

Myasthenia gravis induced by avelumab

August 22, 2019

Anti-TNF therapy given concurrently with ICI therapy may be beneficial in patients with GI irAEs

August 16, 2019

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomized, controlled, phase 3 trial

August 16, 2019

Serum Lactate Dehydrogenase Before Nivolumab Treatment Could Be a Therapeutic Prognostic Biomarker for Patients With Metastatic Clear Cell Renal Cell Carcinoma

August 16, 2019

ADXS-NEO Provoked Strong Immune Response in Advanced Cancer Patient, Early Trial Data Show

August 14, 2019

ICIs may trigger rare form of bullous pemphigoid

July 27, 2019

Wealth of Immunotherapy Combinations Places Emphasis on Biomarkers for NSCLC

July 26, 2019

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

July 25, 2019

Update on Frontline Nivolumab/Ipilimumab Combo Demonstrates Positive OS Results in PD-L1+ NSCLC

July 19, 2019

Prophylactic anti-TNF Therapy Improves Safety of Immunotherapies, Mouse Study Says

July 12, 2019

Libtayo Approved in Europe to Treat Metastatic or Advanced Cutaneous Squamous Cell Carcinoma

July 10, 2019

Trial Will Test Thermal Ablation, Followed By IP-001 Immunotherapy, Against Solid Tumors

June 19, 2019

Implementation of a Multidisciplinary Approach for Managing Immunotherapy-Related Toxicities

June 18, 2019

Colorectal Cancer Vaccine Candidate Induces Potent Immune Responses, Interim Trial Results Show

June 18, 2019

Phase 1 Study Demonstrates Safety of Pembrolizumab in Patients With HIV and Advanced Cancer

June 18, 2019

Keytruda approved for metastatic small cell lung cancer that has progressed after previous treatment

June 4, 2019

Alternate Doses of Ipilimumab Show Similar Results in Advanced Melanoma

May 27, 2019

Last Patient Enrolled in the Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Advanced Lung Cancer (NSCLC)

May 22, 2019

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study

May 17, 2019

Nivolumab with ipilimumab: Combination has added benefit in advanced renal cell carcinoma

May 16, 2019

First-Line Therapy for Metastatic RCC Remains Controversial Amid New Approvals

May 16, 2019

Immunotherapy response differs by EFGR mutation subtype

May 16, 2019

FDA approves Bavencio with Inlyta for patients with advanced renal cell carcinoma

May 14, 2019

Adopted cell transfer therapy being studied in sarcoma

May 2, 2019

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.

May 1, 2019

Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

April 30, 2019

Keytruda-Inlyta combo approved by FDA for untreated advanced kidney cancer

April 22, 2019

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Inlyta® (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC)

April 16, 2019

Clinical Trial in Ireland Investigates Cellular Immunotherapy as Treatment for Two Autoimmune Liver Diseases

April 15, 2019

The Gut Microbiome & Cancer Immunotherapy

April 15, 2019

Recent Clinical Trials Explore Immunotherapies for Urothelial Carcinoma

April 15, 2019

Cancers ‘change spots’ to avoid immunotherapy

April 12, 2019

TKI-Immunotherapy Combinations Push the Envelope in Frontline RCC

April 11, 2019

First Off-the-Shelf Immunotherapy Clinical Trial Launched

April 11, 2019

FDA Expands Keytruda Indication for First-Line Treatment of Non-Small Cell Lung Cancer

April 10, 2019

Comorbidities Result in Fewer Patients in Clinical Trials

April 10, 2019

Researchers Develop Treatment That Turns Tumors Into Cancer Vaccine Factories

April 10, 2019

AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancer

April 9, 2019

Incysus Therapeutics gets FDA approval for brain cancer treatment trial

April 9, 2019

SWOG cancer research network study opens window into immune microenviroment

April 9, 2019

The changing landscape of diagnostic biomarkers: Exploring the one-biomarker-per-drug paradigm in oncology

April 8, 2019

Cancer ‘vaccine’ shows promise in human trial of lymphoma patients

April 8, 2019

Clinical Trial Investigates Orbsen Therapeutics’ ORBCEL-C™ Immunotherapy as Treatment for Two Autoimmune Liver Diseases

April 7, 2019

Researchers Develop “Swiss Army Knife” Immunotherapy to “Kick and Kill” HIV

April 5, 2019

Fecal transplants could help patients on cancer immunotherapy drugs

April 2, 2019

Gut microbes can spur immune system to attack cancer

April 1, 2019

UC San Diego Health Treats 1st Cancer Patient with Stem-Cell Derived Natural Killer Cells

April 1, 2019

Despite research boom, few immunotherapy studies targeting pancreatic cancer

April 1, 2019

How immune cells help tumors escape body’s defenses

March 31, 2019

AACR 2019 Research Roundup: Pancreatic Cancer Immunotherapy, Prostate Cancer Drug Resistance, Insight into Inherited Cancer Mutations

March 30, 2019

ETH researchers take major step towards personalized cancer immunotherapy

March 29, 2019

Combining DNA Damage Response Inhibitors with Immunotherapy Boosts SCLC Clearance, Mouse Study Shows

March 29, 2019

Immunotherapy for Pre-Cancerous Lesions May Reduce Skin Cancer Risk Over Time

March 28, 2019

Harnessing T-cell “stemness” could enhance cancer immunotherapy

March 28, 2019

Better Muscle Mass Linked to Improved Immunotherapy Response

March 28, 2019

New study confirms EpCAM as promising target for cancer immunotherapy

March 24, 2019

Bladder Cancer Guidelines Showcase Advent of Immunotherapy

March 22, 2019

FDA Approves Tecentriq/Chemo for Newly Diagnosed Extensive-stage SCLC

March 21, 2019

Immunotherapies for Staphylococcus aureus

March 21, 2019

Imugene gains guidance for KEY-Vaxx Immunotherapy development

March 21, 2019

New U.K. Partnership Aims To Improve Access Immunotherapy For Cancer Patients

March 21, 2019

OHSU Knight Cancer Institute Throws Out Old System Of Clinical Trials

March 20, 2019

EU Approves Keytruda/Chemo Combo to Treat Metastatic Squamous NSCLC

March 18, 2019

Immunotherapy Approved for Triple-Negative Breast Cancer

March 18, 2019

Cytovation Initiates Clinical Development Programme With CyPep-1, a First-in-class Lytic Agent for Tumor Immunotherapy

March 15, 2019

TC BioPharm, Trinity College Dublin Pair to Develop Cancer-fighting Cell Therapy

March 13, 2019

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

March 13, 2019

Immune Checkpoint Inhibitors Safe, Effective in HIV-positive Patients with Advanced Cancer, Research Reveals

March 12, 2019

Harness the immune system to fight colon cancer

March 11, 2019

FDA Approves Tecentriq-Abraxane Combo as First Immunotherapy Regimen for Breast Cancer

March 11, 2019

Unique Immunotherapy Combinations Provide an Optimistic Outlook in Early Urothelial Carcinoma Trials

March 8, 2019

Precision drugs could unmask cancers to immune system and boost effects of immunotherapy

March 8, 2019

FDA approves 1st immunotherapy drug to treat breast cancer

March 8, 2019

Immunotherapy in Bladder Cancer

March 8, 2019

More News! Targeting tuberculosis, light-activated drugs, cancer immunotherapies and more

March 8, 2019

Recognizing Endometrial Tumor Immune Features Is Key to Treatment Success

February 26, 2019

Patient-Reported Side Effects: A Crucial Part of Cancer Clinical Trials

February 26, 2019

A Growing Focus on Rare Cancers in Phase I Trials

February 26, 2019

Expert Addresses Toxicity Management for Approved CAR T-Cell Therapies

February 21, 2019

A New Treatment in Oral Immunotherapy Can Relieve Food Allergies, But Few Doctors Offer It

February 21, 2019

Merck in $300M Immune Design boost to Keytruda

February 19, 2019

Merck Provides Update on KEYNOTE-240, a Phase 3 Study of KEYTRUDA® (pembrolizumab) in Previously Treated Patients with Advanced Hepatocellular Carcinoma

February 13, 2019

Keytruda combo outshines Opdivo in kidney cancer

February 13, 2019

Positive Results Reported in Phase 1 Trial of Bavencio for Malignant Mesothelioma

February 13, 2019

Finding the Right Combination for Neoadjuvant Therapy in High-Risk, Stage III Melanoma

February 12, 2019

Tuberculosis—Inhibiting host cell death with immunotherapy

February 12, 2019

Bavencio Shows Promise in Phase 1 Trial of Heavily Treated Malignant Mesothelioma Patients

February 12, 2019

Merck and Pfizer combination therapy improves kidney cancer survival

February 11, 2019

Merck Drug Found to Extend Lives of Brain-Cancer Patients

February 11, 2019

FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

February 8, 2019

GE Healthcare, Vanderbilt University Medical Center to Develop Apps that Predict Immunotherapy Responses

February 7, 2019

Immunotherapy appears better than chemotherapy for aggressive type of skin cancer

February 6, 2019

FDA Expands Alimta’s Label for Initial Treatment of Metastatic Lung Cancer

February 5, 2019

Phase 1b Trial of ADCT-301 in Advanced Solid Tumors Doses First Patient

February 4, 2019

Emerging Immunotherapy Approaches For Urothelial Cancer

February 1, 2019

Tumors with More Mutations Respond Better to Immunotherapy, Study Suggests

January 31, 2019

FDA Expands Alimta Approval for Use With Immunotherapy and Chemo in Lung Cancer

January 31, 2019

Lung-MAP Trial Opens Enrollment to Patients With All Types of NSCLC

January 29, 2019

Brahmer Highlights Immunotherapies in the Pipeline for NSCLC

January 29, 2019

Could an immunotherapy treatment from Israel cure cancer?

January 29, 2019

Clinical trials offer opportunity for breakthroughs in cancer treatment; increased participation is key

January 29, 2019

CAR T Cells Get an Invisibility Cloak

January 28, 2019

Blocking pro-fibrosis pathway may improve immunotherapy of metastatic breast cancer

January 25, 2019

Immunotherapy Drug Avelumab Could Extend Survival for Patients with Unresectable Mesothelioma 

January 24, 2019

Ongoing Study Looks to Bring Immunotherapy to Presurgical Setting in HCC

January 17, 2019

Mesothelioma Researchers Seek More Effectiveness from Immunotherapy

1/11/2019

VISTA checkpoint implicated in pancreatic cancer immunotherapy resistance

1/11/2019

Keytruda Receives Five New Approvals in Japan, Including 3 Expanded Uses for Lung Cancer

1/9/2019

Phase 3 Trial Explores Cabometyx-Tecentriq Combo Therapy in Advanced Liver Cancer

1/9/2019

FDA OKs Phase 2 Trial of AE37-Keytruda Combo in Metastatic Triple-negative Breast Cancer

1/9/2019

Does the Cost Outweigh the Benefit for CAR T-Cell Therapy?

1/9/2019

New clinical trial highlights haNK cell therapy in combination with IL-15 superagonist N-803 and avelumab

1/8/2019

Immune to cancer’s return? The day could be coming

1/7/2019

AVID200, which reverses immunosuppression to enhance sensitivity to checkpoint blockade, enters phase I trial

12/20/2018

AZ/Merck & Co get new US use for ovarian cancer drug

12/19/2018

Advanced melanoma trial when Keytruda alone is not enough

12/19/2018

Keytruda Seen as ‘Kinder’ and Superior to Standard Therapies for Advanced Head and Neck Cancer Patients in Phase 3 Trial

12/18/2018

Researchers identify ways breast cancer avoids immune system detection

12/18/2018

Metal chemotherapy drugs boost the impact of immunotherapy in cancer

12/18/2018

Phase 3 Trial to Test GPS Vaccine as Maintenance Therapy in High-risk Acute Myeloid Leukemia Patients

12/14/2018

AMG 330 Immunotherapy Shows Promise in Relapsed or Refractory Acute Myeloid Leukemia

12/6/2018

FDA approves Genentech drug for lung cancer

11/27/2018

Generex Biotechnology Signs Clinical Trial Agreement with the NSABP Foundation, Inc. for Phase II Clinical Trial of AE37 in Combination with Pembrolizumab (Keytruda®) for Treatment of Triple-Negative Breast Cancer

11/27/2018

Opdivo-Yervoy Combo Delays Need for Additional Treatment in Renal Cell Carcinoma Patients, Phase 3 Data Shows

11/26/2018

Bristol-Myers Squibb Announces CheckMate -451 Study Did Not Meet Primary Endpoint of Overall Survival with Opdivo Plus Yervoy Vs. Placebo as A Maintenance Therapy in Patients with Extensive-Stage Small Cell Lung Cancer After Completion of First-Line Chemotherapy

11/26/2018

Nivolumab/Ipilimumab Combo Misses Primary Endpoint in Phase III SCLC Trial

11/26/2018

Avelumab Fails to Meet Primary Endpoints in Phase III Ovarian Cancer Trial

11/25/2018

Combos Pairing Inhibitors of Angiogenesis and Immune Checkpoints Have Potential

11/21/2018

Durable Responses Seen With Atezolizumab in Advanced Alveolar Soft Part Sarcoma

11/6/2018

CheckMate 067 Gives Nivolumab Alone, With Ipilimumab the Nod in Advanced Melanoma

11/5/2018

Quick Take: Phase Ib/II Study of Pembrolizumab and Pegylated Interferon Alfa-2b in Advanced Melanoma

10/18/2018

Antiangiogenics and Immunotherapy Combos Show Promising Activity in Solid Tumors

10/17/2018

Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC